- Pin
- Not sure how to use your Gate Post Growth Points? We've got you covered!
Growth Points Lucky Draw Round 1️⃣ 1️⃣ is coming soon!
Post, comment, like, and join chats daily to earn more Growth Points and win amazing prizes!
➡️ https://www.gate.io/post
🔥 This round features upgraded prizes — with surprise rewards waiting for you!
For more Growth Points tasks, tap the Growth Points icon next to your Gate Post avatar.
Thank you for your support and engagement — we’re here to reward your every effort!
#CommunityGrowthPoints#
- ⏰ Just a Few Days Left!
🔥 The 12th Anniversary Celebration is Ending Soon — Don’t Miss Your Chance to Claim Rewards
🚀 Limited-Time Revelry #5 is Live
👉 Log in & play to win iPhone 16 Pro, MacBook Air and more: https://www.gate.com/activities/12th-anniversary
🏆 Draw for merch & send greetings on the Greeting Wall to win exclusive merch prizes
More Details: https://www.gate.com/announcements/article/44624
#Gate12Years#
- 🔥 Gate Post Ambassador Exclusive Posting Reward Task Round 2 Is On! 🏆 Round 1 winners will be announced on May 26!
Sign up now 👉 https://www.gate.com/questionnaire/6722
Registration Period 🕙 May 23, 03:00 AM – May 26, 04:00 PM UTC
✍️ Post daily from May 26 to June 1 and share a $300 prize pool based on your post quality!
🎁 Reward Details:
S-Level Weekly Ranking Reward
Post every day for 7 days with an overall quality score above 90 to qualify for S-Level.
2 outstanding ambassadors will each receive a $50 trading fee rebate voucher.
A/B-Level Tiered Rewards
Based on the number of posts and
- 🎉 #Gate Post# Hits 50,000 Followers!
✨ To celebrate this amazing milestone, we're giving back to our incredible community!
🎁 4 Lucky Winners Will Each Receive $10 Points!
Join:
1️⃣ Follow Gate_Post
2️⃣ Like this post
3️⃣ Drop your congratulations in the comments!
End at 18:00, May 25 (UTC)
- 🔥 Gate Post Ambassador Exclusive Posting Reward Task Is On!
👉 Post daily from May 19 to May 25 and share a $300 prize pool based on your post quality!
Join now: https://www.gate.io/questionnaire/6679
Registration deadline: May 20 10:00 UTC
🎁 Reward Details:
S-Level Weekly Ranking Reward
Post every day for 7 days with an overall quality score above 90 to qualify for S-Level.
2 outstanding ambassadors will each receive a $50 trading fee rebate voucher.
A/B-Level Tiered Rewards
Based on the number of posts and their quality, ambassadors will be ranked and rewarded accordingly:
A-Level:
Post on
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.